NCT04975932

Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study

Efficacy and Safety of Transarterial Chemoembolization in Combination With Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: a Real-world Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 826 (actual)
• Sponsor: Zhongda Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) .

Detailed description

Transarterial chemoembolization (TACE) can induce immunogenic cell death and tumor-specific immune response which results in the release of tumor antigens and transform "cold" tumors with lacking immune effector cells into "hot" tumors with immune effector cells infiltration. This provides a theoretical basis for TACE combined with immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) patients. The purpose of this study is to evaluate the safety and efficacy of TACE in combination with ICIs in patients with HCC. This real-world study also explores the optimal combined treatment and outcome of HCC patients for providing further information for clinical practice and trials.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
OTHER	TACE+ICIs	TACE plus ICIs ( with or without molecular targeted therapies)
PROCEDURE	TACE	TACE without combination of ICIs ( with or without molecular targeted therapies)

Timeline

• Start date: 2021-07-01
• Primary completion: 2022-05-31
• Completion: 2023-02-08
• First posted: 2021-07-26
• Last updated: 2023-07-14

Locations

1 site across 1 country: China